Increase In High-density Lipoprotein Cholesterol Levels Research Articles

Semaglutide for the treatment of obesity

Introduction and purpose
 Due to the growing tendency to diagnose obesity in patients, scientists are trying to find drugs that facilitate weight reduction. 
 An example of such a formulation is the GLP-1 analogue semaglutide. The following article is an analysis of the current knowledge on the effectiveness and safety of obesity treatment with semaglutide based on available publications in Pubmed and Google Scholar databases.
 State of knowledge
 The main mechanism of semaglutide is based on a stimulation of insulin secretion from pancreatic beta cells, and inhibition of glucagon from alpha cells, inhibition of hepatic gluconeogenesis, and reduction of energy consumption with minimal impact on energy expenditure. In clinical trials, it showed the best results compared to placebo and other drugs used in weight reduction. Participants treated with semaglutide achieved a reduction in waist circumference, improvements in blood pressure parameters, HbA1c levels, total cholesterol, LDL cholesterol, triglycerides, and CRP protein, and increased HDL cholesterol levels. Semaglutide is well tolerated by patients, and its main side effects come from the gastrointestinal tract, including nausea, emesis, diarrhea.
 Summary
 The analysis of the latest publications and meta-analyzes of the literature shows that the use of semaglutide is safe and effective in the treatment of obesity. The positive effect of semaglutide on weight reduction also contributes to the reduction of the risk of cardiovascular events and other obesity-related complications. It is also well tolerated by patients, which translates into possible longer use, and weekly subcutaneous injections are not burdensome for patients.
 Key words: semaglutide; obesity; GLP-1 analogue; overweight

FRAKSI EKSTRAK ETANOL BUAH PARE (Mommordica charantia L.) SEBAGAI ANTIINFLAMASI TERHADAP KADAR TUMOR NECROSIS FACTOR ALPHA (TNF-α)

Dyslipidemia is an abnormality of lipids in the blood, including a decrease in HDL levels and an increase in triglyceride levels, LDL levels and total cholesterol. The high concentration of cholesterol in the blood is one of the causes of atherosclerosis and can further cause hypertension and coronary heart disease. The use of synthetic drugs in the long term can cause unwanted side effects. This study aims to examine the effect of increasing HDL cholesterol levels, decreasing total cholesterol and LDL cholesterol levels from the ethanol extract of Clitoria ternatea L using male rats (Rattus norvegicus). This study used the maceration method of Clitoria ternatea L. then the thick extract obtained was tested for its activity which was divided into 6 treatment groups namely normal control group, positive control, negative control, dose 1 (extract 100 mg/kgBB), dose 1 2 (extract 200 mg/kgBB) and dose 3 (extract 400 mg/kgBB) were then measured for total cholesterol, HDL and LDL. The results showed that the administration of ethanol extract of Clitoria ternatea L was able to reduce total cholesterol levels, LDL and increase HDL levels in male rats. The dose of ethanol extract of Clitoria ternatea L that was most effective in reducing total and LDL cholesterol levels and increasing HDL levels in rats that had been induced by a high-fat diet was dose 3, namely extract 400mg/kgBB.

Anthocyanins-rich interventions on oxidative stress, inflammation and lipid profile in patients undergoing hemodialysis: meta-analysis and meta-regression.

The aim of this systematic review and meta-analysis was to evaluate the effects of anthocyanins-interventions on oxidative stress, inflammation, and lipid profile in patients undergoing hemodialysis. This systematic review and meta-analysis were registered on the International Prospective Register of Systematic Reviews (PROSPERO CRD42020209742). The primary outcome was anthocyanins-rich intervention on OS parameters and secondary outcome was anthocyanins-rich intervention on inflammation and dyslipidemia. RevMan 5.4 software was used to analyze the effect size of anthocyanins-rich intervention on OS, inflammation and dyslipidemia. Meta-analysis effect size calculations incorporated random-effects model for both outcomes 1 and 2. Eight studies were included in the systematic review (trials enrolling 715 patients; 165 men and 195 women; age range between 30 and 79 years). Anthocyanin intervention in patients undergoing hemodialysis decrease the oxidant parameters (std. mean: -2.64, 95% CI: [-3.77, -1.50], P ≤ 0.0001, I2 = 97%). Specially by reduction of malondialdehyde products in favor of anthocyanins-rich intervention (std. mean: -14.58 µmol.L, 95% CI: [-26.20, -2.96], P ≤ 0.0001, I2 = 99%) and myeloperoxidase (std. mean: -1.28 ηg.mL, 95% CI: [-2.11, -0.45], P = 0.003, I2 = 77%) against placebo group. Decrease inflammatory parameters (std. mean: -0.57, 95% CI: [-0.98, -0.16], P = 0.007, I2 = 79%), increase HDL cholesterol levels (std. mean: 0.58 mg.dL, 95% CI: [0.23, 0.94], P = 0.001, I2 = 12%) against placebo group. Anthocyanins-rich intervention seems to reduce oxidative stress, inflammatory parameters and improve lipid profile by increasing HDL cholesterol levels in patients with chronic kidney disease undergoing hemodialysis.

A Comparative Study on Clinical Evaluation of the Hypolipidemic Effects of Allium sativum, Trigonella foenum-graecum, Commiphora mukul, Picrorhiza kurroa, and Piper nigrum: A Pilot Study.

BackgroundCardiovascular disease is a leading cause of morbidity and mortality. Therefore, it is essential to prevent cardiovascular diseases by correcting modifiable risk factors such as lowering lipid levels, lowering blood pressure, improving eating habits, giving up smoking, etc. The present study assessed the efficacy of herbal preparation containing Allium sativum (A. sativum), Commiphora mukul (C. mukul), and Trigonella foenum-graecum (T. foenum-graecum) in patients with hyperlipidemia.MethodologyPatients were given extracts of A. sativum 350 mg, T. foenum-graecum 350 mg, C. mukul 200 mg, Picrorhiza kurroa (P. kurroa) 200 mg, and Piper nigrum (P. nigrum) 5 mg. Unichem Laboratories, Mumbai, provided placebo tablets similar in shape and size to herbal tablets. Patients were assessed for compliance, and a complete lipid profile was done at DO, D15, D46, D76, and D106. In addition, total cholesterol and high-density lipoprotein-cholesterol (HDL-C) serum triglyceride were estimated by the respective methods throughout the study.ResultsThe weight of the patients remained stable, the mean weight before being 65.42 ± 8.35 kg and after completion of the study being 65.42 ± 8.35 kg. There were no changes in the ECG during or after the drug therapy in any of the patients. Group A comprised nine patients, and group B had ten patients. Serum creatinine (mg %) was 0.94 and 0.95, fasting blood sugar mg (%) was 111.05 and 99.63, and postprandial blood sugar (mg %) was 150.89 and 147.94 on pre-treatment and post-treatment, respectively. The mean serum triglyceride levels in group A were 271.11, 261.11, 293.89, 167.22, and 128.89, and serum HDL- C levels were 46.11, 46.11, 54.44, 52.22, and 54.44. Serum triglyceride levels in group B were 268, 268.5, 202, 171, and 116, and serum HDL- C levels were 48.5, 48, 50, 50, and 53.5 on day 0, 15, 46, 76, and 106, respectively. A significant reduction in total cholesterol levels was observed on D46, D76, and D106, with a maximum reduction on D76 (25.36%). Similarly, a reduction in serum triglyceride was also observed on D46, D76, and D106, with a maximum reduction on D106 (52.02%). A significant difference was observed (P <0.05). There was also a significant reduction of low-density lipoprotein cholesterol (LDL-C) on D46, D76, and D106, with the maximum reduction on D76 (28.79%). There was a significant rise of HDL-C on D46 and D106, with a maximum rise on D106 (15.41%). A significant difference was observed (P <0.05).ConclusionThe study drugs are safe and efficacious in reducing the total cholesterol, serum triglycerides, LDL-C levels, and increasing HDL-C levels.

Role of Phytoestrogen-Rich Bioactive Substances (Linum usitatissimum L., Glycine max L., Trifolium pratense L.) in Cardiovascular Disease Prevention in Postmenopausal Women: A Systematic Review and Meta-Analysis.

The aim of this report was to determine the impact of flaxseed, soy and red clover, and their bioactive substances on the lipid profile in postmenopausal women in cardiovascular diseases prevention. We used the following databases: MEDLINE (PubMed), EMBASE and the Cochrane Library. Meta-analysis indicates that the intake of flaxseed by postmenopausal women is associated with a statistically significant reduction in total cholesterol (TC) levels (weighted-mean difference (WMD) = −0.26; 95% confidence interval (95% CI): −0.38 to −0.13; p = 0.0001), low-density lipoprotein cholesterol (LDL-C) levels (WMD = −0.19; 95% CI: −0.30 to −0.08; p = 0.0006), and high-density lipoprotein cholesterol (HDL-C) levels (WMD = −0.06; 95% CI: −0.11 to −0.01; p = 0.0150). The effect of soy protein on the lipid profile showed a significant decrease in TC levels: WMD = −0.15; 95% CI: −0.25–0.05; p = 0.0048, LDL-C levels: WMD = −0.15; 95% CI: −0.25–0.05; p = 0.0067, as well as a significant increase in HDL-C levels: WMD = 0.05; 95% CI: 0.02–0.08; p = 0.0034. Changes in the lipid profile showed a significant reduction in TC levels after the use of red clover (WMD = −0.11; 95% CI: −0.18–−0.04; p = 0.0017) and a significant increase in HDL-C levels (WMD = 0.04; 95% CI: 0.01 to 0.07; p = 0.0165). This meta-analysis provides evidence that consuming flaxseed, soy and red clover can have a beneficial effect on lipids in postmenopausal women and suggest a favorable effect in preventing cardiovascular diseases.

Caffeic acid regulates glucose homeostasis and inhibits purinergic and cholinergic activities while abating oxidative stress and dyslipidaemia in fructose-streptozotocin-induced diabetic rats.

The antidiabetic potential of caffeic acid in fructose/streptozotocin-induced type 2 diabetic rats was examined in this study. Male Sprague-Dawley rats were supplied with 10% fructose solution for 14 days followed by an intraperitoneal injection of 40 mg/kg bw streptozotocin to induce type 2 diabetes (T2D). Rats were treated with both low (150 mg/kg bw) and high (300 mg/kg bw) doses of caffeic acid for 5 weeks, while the positive control group was treated with metformin (200 mg/kg bw). Treatment with caffeic acid significantly decreased blood glucose levels and elevated serum insulin levels while improving glucose tolerance, pancreatic β-cell function and morphology. It also led to a significant reduction of serum cholesterol, triglyceride, LDL-cholesterol, ALT, AST, creatinine, urea and uric acid levels, while increasing HDL cholesterol levels. Caffeic acid significantly (P < 0.05) elevated hepatic glycogen level, serum and pancreatic glutathione level, superoxide dismutase and catalase activities with a concomitant decrease in malondialdehyde level, α-amylase, lipase, adenosine triphosphatase (ATPase), ectonucleoside triphosphate diphosphohydrolase (ENTPDase), 5'-nucleotidase (5'-NTD) and acetylcholinesterase activities. The results suggest caffeic acid as a potent natural product with therapeutic effects against T2D. Further molecular and clinical studies are, however, required to ascertain these findings.

The effect of vitamin D on the lipid profile as a risk factor for coronary heart disease in postmenopausal women: a meta-analysis and systematic review of randomized controlled trials

The exact effect of vitamin D administration on the lipid profile in postmenopausal women is unknown. However, as dyslipidemia is a recognized risk factor for coronary heart disease (CHD) in this population, the lipid-lowering effects of vitamin D need to be explored Thus, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) that evaluated the impact of vitamin D use on triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) as a risk factor for coronary heart disease (CHD) in postmenopausal women. We developed a search strategy for multiple databases (PubMed/Medline, Scopus, Embase, and Web of Science) to identify relevant RCTs whose results were published until June 1st, 2021. We combined the results using a random effects model (the DerSimonian and Laird random effects model). Lipid profile outcomes were expressed as weighted mean difference (WMD) and 95% confidence intervals (CIs) between intervention and comparator groups. Supplementation with vitamin D decreased TG (WMD: -3.55mg/dL, 95% CI: -5.34 to -1.76, P<0.001) in postmenopausal females versus controls. In the subgroup analyses, vitamin D increased TC when the treatment duration was ˂26weeks (WMD: 6.56mg/dL, 95% CI: 0.78 to 12.35, P=0.02) as compared to ≥26weeks (WMD: -2.06mg/dL, 95% CI: -5.49, 1.36, P=0.23) and in the participants with a BMI ≥30kg/m2 (WMD: 3.65mg/dL, 95% CI: 0.09, 7.22, P=0.044). Moreover, vitamin D increased HDL-C when the treatment duration was ˂26weeks (WMD: 2.67mg/dL, 95% CI: 0.66 to 4.68, P=0.009). In addition, vitamin D decreased LDL-C when the vitamin D dose was ˃400IU/day (WMD: -1.89mg/dL, 95% CI: -2.47 to -1.31, P<0.001) as compared to ≤400IU/day (WMD: 2.50mg/dL, 95% CI: -2.50, 7.52, P=0.327). Vitamin D administration on the lipid profile as a risk factor for CHD in postmenopausal women reduces TG. Its effects to lower LDL-C and increase HDL-C and TC levels are clinically negligible but should be investigated in future research. In addition, supplementation with vitamin D results in a clinically significant reduction in TG, particularly in postmenopausal females with hypertriglyceridemia at baseline.

Effects of N-acetylcysteine supplementation on disease activity, oxidative stress, and inflammatory and metabolic parameters in rheumatoid arthritis patients: a randomized double-blind placebo-controlled trial.

Considering the importance of inflammation and oxidative stress in the development of rheumatoid arthritis (RA) as well as anti-inflammatory and antioxidant features of N-acetylcysteine (NAC), this study was conducted to evaluate the effect of NAC supplementation on disease activity, oxidative stress, and inflammatory and metabolic parameters in RA patients. In a randomized double-masked placebo-controlled trial, 74 RA subjects were chosen and randomly divided into two groups to take 600mg of NAC or placebo twice daily for 3months. Before and after the study, disease activity was assessed via disease activity score-28 (DAS-28), and serum malondialdehyde (MDA), total antioxidant capacity (TAC), glutathione peroxidase (GPX) activity, nitric oxide (NO), high-sensitivity C-reactive protein (hs-CRP), fasting blood sugar (FBS), lipid profile, and erythrocyte sedimentation rate (ESR) were measured. Seventy patients completed the trial. Compared to baseline, NAC significantly reduced morning stiffness (P < 0.001), DAS-28 (P < 0.001), ESR (P = 0.004), MDA (P < 0.001), NO (P < 0.001), hs-CRP (P = 0.006), FBS (P < 0.001), and low-density lipoprotein cholesterol (LDL-C) (P = 0.023) and significantly increased GPx activity (P = 0.015) and high-density lipoprotein cholesterol (HDL-C) level (P = 0.001). After treatment, remarkable differences were only seen between the two groups in serum NO (P = 0.003), FBS (P = 0.010), and HDL-C (P < 0.001) adjusted for baseline measures. There were no significant changes in morning stiffness, DAS-28, ESR, hs-CRP, MDA, TAC, GPx activity, triglyceride, total cholesterol, and LDL-C levels compared to the placebo group. In conclusion, NAC did not improve RA disease activity, but reduced NO and FBS and increased HDL-C levels. It appears that NAC should not be consumed as a replacement for routine medications prescribed in RA therapy, but it can be used as an adjunctive therapy.

Efek Bunga Telang (Clitoria ternatea L.) Terhadap Kolesterol Total, LDL, HDL Pada Tikus (Rattus Norvegicus )

Dyslipidemia is an abnormality of lipids in the blood, including a decrease in HDL levels and an increase in triglyceride levels, LDL levels and total cholesterol. The high concentration of cholesterol in the blood is one of the causes of atherosclerosis and can further cause hypertension and coronary heart disease. The use of synthetic drugs in the long term can cause unwanted side effects. This study aims to examine the effect of increasing HDL cholesterol levels, decreasing total cholesterol and LDL cholesterol levels from the ethanol extract of Clitoria ternatea L using male rats (Rattus norvegicus). This study used the maceration method of Clitoria ternatea L. then the thick extract obtained was tested for its activity which was divided into 6 treatment groups namely normal control group, positive control, negative control, dose 1 (extract 100 mg/kgBB), dose 1 2 (extract 200 mg/kgBB) and dose 3 (extract 400 mg/kgBB) were then measured for total cholesterol, HDL and LDL. The results showed that the administration of ethanol extract of Clitoria ternatea L was able to reduce total cholesterol levels, LDL and increase HDL levels in male rats. The dose of ethanol extract of Clitoria ternatea L that was most effective in reducing total and LDL cholesterol levels and increasing HDL levels in rats that had been induced by a high-fat diet was dose 3, namely extract 400mg/kgBB.

Oxidant resistant human apolipoprotein A-I functions similarly to the unmodified human isoform in delaying atherosclerosis progression and promoting atherosclerosis regression in hyperlipidemic mice.

BackgroundTransgenic overexpression of apolipoprotein A-I (apoA1) has been shown to delay atherosclerosis lesion progression and promote lesion regression in mouse models; however, apoA1 is subject to oxidation by myeloperoxidase (MPO) and loss of function. The activity of oxidant resistant human apoA1 was compared to unmodified human apoA1 in mouse models of atherosclerosis progression and regression.Methods and resultsHuman apoA1 and the MPO oxidant resistant 4WF isoform transgenic mice were bred to LDL receptor deficient (LDLr KO) mice and fed a western-type diet. High level expression of these human apoA1 isoforms did not lead to increased HDL-cholesterol levels on the LDLr KO background. In males and females, lesion progression was studied over time, and both apoA1 and 4WF transgenic mice vs. LDLr KO mice had significant and similar delayed lesion progression and reduced non-HDL cholesterol. Using time points with equivalent lesion areas, lesion regression was initiated by feeding the mice a low-fat control diet containing a microsomal triglyceride transfer protein inhibitor for 7 weeks. Lesions regressed more in the male apoA1 and 4WF transgenics vs. the LDLr KO, but the 4WF isoform was not superior to the unmodified isoform in promoting lesion regression.ConclusionsBoth human apoA1 and the 4WF MPO oxidant resistant apoA1 isoform delayed lesion progression and promoted lesion regression in LDLr KO mice, with more pronounced effects in males than females; moreover, the 4WF isoform functioned similarly to the unmodified human apoA1 isoform.

THE EFFECT OF DIFFERENT FREE FATTY ACID FRACTIONS FROM HYDROLYZED VIRGIN COCONUT OIL ON CHANGES OF LIPID PROFILE AND LIVER MORPHOLOGY INDUCED BY HIGH FAT DIET: AN IN VIVO STUDY

This study investigated effect of virgin coconut oil (VCO)-derived fatty acids on the alteration of lipid profiles and liver tissues of high fat diet (HFD) fed mice. The initial fatty acids mixture was successfully obtained via hydrolysis process using Candida rugosa lipase (CRL). Enrichment of medium chain fatty acids (MCFA) from the initial fatty acid mixture using distillation process was developed to achieve 3 fractions of fatty acids mixture including Fraction I (MCFA mainly from C8 to C10), Fraction II of lauric acid (C12), and Fraction III (long chain fatty acids from C14 to C20). Among these agents, VCO only diminished ALT level but the initial FFA mixture decreased both ALT and AST levels compared with HFD-induced mice. Moreover, Fraction I and Fraction II showed an obvious difference in decreasing ALT, AST, total cholesterol, and LDL cholesterol levels as well as increasing HDL cholesterol level compared to other agents. It was observed a microvesicular steatosis and mild inflammation in liver section of mice fed with HFD whereas VCO, initial fatty acids, and Fraction II showed the beneficial effect on liver damage.

Sex disparities in the effect of statins on lipid parameters: The PharmLines Initiative.

Real-world evidence on a potential statin effect modification by sex is inconclusive, especially for the primary prevention of cardiovascular disease (CVD). We aimed to quantify the differences in the effect of statins on lipid parameters between men and women.The PharmLines Initiative linked the Lifelines Cohort Study and the IADB.nl prescription database. This database covers a representative population from the Netherlands. We selected participants aged ≥40 years at the index date: the date of the first prescription of any statin monotherapy in the study period 2006 to 2017. Multivariate regression modeling was used to compare the difference of the mean percentage change of lipid parameters (% mean difference [MD]) from baseline to follow-up measurement between the sexes.Out of 5366 statin users from approximately 50,000 participants available in the final linked database, 685 were statin initiators. At baseline, women had significantly higher levels of mean total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) than men (all P values <.01). At follow-up, women had a significantly higher mean percentage change of HDL-C compared to men (adjusted % MD 5.59, 95% confidence interval [CI] 2.42-8.75, P < .01). There was no significant sex difference in other parameters, nor in the proportion of men and women who achieved LDL-C ≤2.5 mmol/L.Statins appear to have a greater effect on increasing HDL-C levels in women than men while showing similar effect on other lipid parameters in both sexes. Men should not be treated differently than women.

Skeletal Muscle Mass is Associated with HDL Cholesterol Levels and the Ratio of LDL to HDL Cholesterol in Young Men: A Pilot Study

Background: It is unclear whether greater skeletal muscle mass is beneficial for improving cardiometabolic health in young individuals. Our purpose was to investigate the association between skeletal muscle mass and cardiometabolic risk factors in young males. Methods: Data were collected from thirty-seven young males (23.2 ± 0.3 years). Participants were categorized based on skeletal muscle mass (skeletal muscle index-percentile score, SMI-PS) assessed by bioelectrical impedance analysis. They were divided into two group: standard skeletal muscle mass group (SMG, n = 17, SMI-PS = 102.2 ± 1.0%), high skeletal muscle mass group (HMG, n = 20, SMI-PS = 120.5 ± 1.8%). Arterial stiffness assessed by brachial-ankle pulse wave velocity (baPWV) and blood parameters including high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), fasting glucose (FG) and hemoglobin A1c (HbA1c) were assessed. Results: The level of HDL-C in HMG was significantly higher compared to SMG (p &lt; 0.001), whereas the ratio of LDL-C to HDL-C in HMG was significantly lower compared to SMG (p &lt; 0.001). However, no changes in baPWV, TC, LDL-C, TG, FG, and HbA1c were found between groups. Interestingly, there was a positive correlation between SMI-PS and HDL-C (r = 0.469, p = 0.003), whereas there was a negative correlation between SMI-PS and LDL-C/HDL-C (r = –0.38, p = 0.02). Conclusions: This study suggests that an increase in skeletal muscle mass may have an additive benefit on improving lipid components through the increased HDL-C level and decreased the ratio of LDL-C to HDL-C in young men.

Hypolipidemic Effect and Liver Protection of Irpex lacteus Fermented Tea in Vivo

To study the effect of Irpex lacteus fermented tea on blood lipids and liver in mouse, 60 male KM mice were established hyperlipidemia model by high-fat diet induction, and then were randomly divided into six groups: Model group, simvastatin positive control group(10 mg/kg), green tea group(400 mg/kg) and high-(400 mg/kg), medium-(200 mg/kg), and low-(100 mg/kg) -dose Irpex lacteus fermented tea groups. And another 10 male KM mice were set up blank control group. The blank control group was given basic feeds, and the remaining groups were fed with high-fat feeds and gavage corresponding drugs. After 35 days, the body weight, liver weight and liver coefficient of each group were calculated. Serum total cholesterol(TC), triglyceride(TG), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), aspartate aminotransferase(AST), alanine aminotransferase(ALT), alkaline phosphatase(ALP), superoxide dismutase(SOD), malondialdehyde(MDA) and glutathion peroxide(GSH) levels were detected, and morphological changes(HE) and liver fat particles(oil red O) in the liver of mice were observed. The results showed that high-(400 mg/kg) -dose Irpex lacteus fermented tea group could significantly reduce the levels of TC, LDL-C, AST, ALT, ALP and liver coefficient(P<0.05 or P<0.01), these indicators levels were close to the simvastatin group. High-(400 mg/kg) -dose Irpex lacteus fermented tea group significantly reduced TG level(P<0.01), and with the blank control group TG level, and increased HDL-C levels(P<0.01) in hyperlipidemic mice, the level of HDL-C was close to simvastatin group. It also could significantly reduce MDA content in liver and hyperlipidemia mice below simvastatin group, and increase SOD and GSH activity, which were close to blank control group and simvastatin group, respectively(P<0.05), improve the degree of fatty liver histopathology, and reduce liver fat particles. These findings indicated that the high-(400 mg/kg) -dose Irpex lacteus fermented tea group had hypolipidemic, improved the fatty liver disease and hepatoprotective effects by regulating oxidative stress in hyperlipidemic mice. This study would provide a theoretical basis for the development and utilization of the Irpex lacteus fermented tea as functional tea with anti-oxidation, lowering blood lipid and improving fatty liver.

Dynamics of body weight during lifestyle modification in patients with high cardiovascular risk, depending on the carriage of various variants of thrifty genes

Objective — to study the relationship between the carriage of polymorphic variants PPARG2 (Pro12Ala), ADRB2 (Gln27Glu), ADRB2 (Agr16Gly), ADRB3 (Trp64Agr), FABP2 (Thr54Ala) and changes in anthropometric parameters under the influence of increased physical activity in individuals with high cardiovascular risk.&#x0D; Materials and methods. In total, 205 people were examined during the period of years 2019 — 2021. Patients were advised to use physical activity frequently in the form of regular exercises. Among patients who passed the 2nd observation point, 60.5 % (124 patients) reported that they expanded their physical activity, 39.5 % (81 patients) began regular exercises. The study included patients with high cardiovascular risk. The International Physical Activity Questionnaire (IPAQ) was used to assess physical activity. Assessments included anthropometric parameters (weight, height, body mass index, waist and hip circumference, body composition (Composition Monitor BF511, Omron, China, 2015)), levels of total cholesterol, triglycerides, low‑density lipoproteins. Muscle strength (kg/cm2) was assessed using an electric dynamometer on the wrist Camry EH101 2013 (2018). Isolation and purification of DNA from the whole blood was carried out using a set of reagents «DNA‑sorb‑B» (Amplisens, RF) according to the manufacturer’s instructions. Amplification of DNA and genotyping at polymorphic sites in the genes PPARG2, ADRB2, ADRB3, FABP2 was performed by real‑time PCR using a set of reagents «SNP‑EXPRESS‑SHOT» («Litech», RF) according to the manufacturer’s instructions using the product detection system real‑time CFX96 Touch (BioRad Laboratories Pte.Ltd.).&#x0D; Results. Depending on the changes in anthropometric parameters, patients were divided into 2 subgroups: in subgroup 1 there was no decrease in BMI before 30.69 ± 7.25 kg/m2, after 29.03 ± 6.84 kg/m2; p = 0.436, and in subgroup 2 a significant decrease in BMI before 31.85 ± 3.68 kg/m2, after 26.79 ± 3.91 kg/m2; p = 0.041. It was revealed that the decrease in BMI in subgroup 2 was accompanied by a statistically significant decrease in the proportion of adipose tissue (р = 0.011) and an increase the proportion of muscle tissue (р = 0.030). In both groups, blood pressure significantly decreased. Heart rate (HR) decreased in both groups, but these changes did not reach statistical significance (p = 0.43). Changes in anthropometric parameters were not accompanied by significant changes in total cholesterol, LDL cholesterol, triglycerides levels. A significant increase in HDL cholesterol levels was revealed. It was found that patients with CC and GG variants of the polymorphic locus PPARG2 (Pro12Ala), CG and GG variants of the polymorphic locus ADRB2 (Gln27Glu) and TT variant of the polymorphic locus ADRB3 (Trp64Agr) prevailed in group 2. No significant differences were found for the FABP2 locus (Thr54Ala). In subgroup 1, there were no significant differences in people with various polymorphic variants of genes.&#x0D; Conclusions. Associations have been established between the carriage of CG/CG + GG PPARG2 (rs1801282), AA/AA + AG ADRB2 (rs1042713) and TT ADRB3 (rs4994) and a decrease in body mass index during exercise expansion in individuals with high cardiovascular risk.&#x0D;

The Potential of ANGPTL8 Antagonism to Simultaneously Reduce Triglyceride and Increase HDL-Cholesterol Plasma Levels.

Elevated triglyceride (TG) and reduced high-density lipoprotein-cholesterol (HDL-C) plasma levels are risk factors for atherosclerosis and cardiovascular disease. Therefore, a drug that simultaneously reduces TG and increases HDL-C plasma levels has the potential to prevent and treat these diseases. Angiopoietin-like 3 (ANGPTL3) regulates plasma TG and HDL-C levels by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL), respectively. ANGPTL3 inhibition of LPL requires complex formation with ANGPTL8, which is not required for its inhibition of EL. Therefore, the entire pool of plasma ANGPTL3 can be classified as ANGPTL8-associated ANGPTL3 and ANGPTL8-free ANGPTL3, where the former inhibits LPL and the latter inhibits EL. ANGPTL8 antibodies or inhibitors that block its interactions with ANGPTL3 can disrupt or preclude the ANGPTL3-8 complex formation, resulting in fewer ANGPTL3-8 complexes (reduced LPL inhibition), but more free ANGPTL3 (enhanced EL inhibition). Therefore, ANGPTL8 antagonism increases LPL activity while decreasing EL activity, thus leading to reduced plasma TG while simultaneously increasing HDL-C levels. In humans, carriers of ANGPTL8 truncating variants consistently have lower TG but higher HDL-C levels, supporting this hypothesis.

Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study.

Background/Aim: The recovery pattern of hepatitis C virus (HCV)-associated metabolic alteration after sustained virological response (SVR) following direct-acting antivirals (DAAs) remains elusive. Methods: A prospective cohort study of chronic HCV-infected (CHC) patients (n = 415) receiving DAAs (n = 365) was conducted. Metabolic profiles were examined in SVR patients (n = 360) every 3–6 months after therapy and compared with those of sex- and age-matched controls (n = 470). Results: At baseline, of 415, 168 (40.5%) had insulin resistance (IR). The following were associated: levels of high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), HCV RNA, fibrosis-4 score, and interferon-λ3-rs12979860 genotype with total cholesterol (TC) levels; and TG levels and BMI with HOMA-IR. Over a 3-year follow-up, in SVR patients, BMI and TC levels and TG/HDL-C ratios increased from baseline, while HOMA-IR trended downward by 72 weeks after therapy and then increased. The increased HDL-C levels began to decrease after 72 weeks after therapy. TC and HOMA-IR were negatively associated with each other until 24 weeks after therapy. Earlier increases in BMI and decreases in HOMA-IR were noted in SVR patients with than in those without baseline IR. Compared with controls, in the subgroup without baseline IR, SVR patients had increased BMI and HOMA-IR levels. Metabolic profiles were similar between SVR patients and controls in the subgroup with baseline IR. Conclusions: In SVR patients treated with DAAs, the recovery of altered lipid and glucose metabolism was not coupled until 72-week post-therapy, when HOMA-IR reached its nadir. SVR patients with baseline IR recovered from HCV-associated metabolic alterations earlier than those without baseline IR.

Formulation, Evaluation of Physical Properties, Anti-Cholesterol Activity from Ficus carica L. Leaves Extract Tablet

Figs knew playing vital roles in reducing cholesterol, strengthening the heart, and controlling respiration. Figs leaves extract with a dose of 50 mg/kg and 100 mg/kg can reduce triglyceride levels and can increase HDL cholesterol levels. This study aims to determine the effect of Ficus carica L. (fig) leaves extract on tablet dosage forms to reducing total cholesterol in rats induced with pork fat feed. Tablets were made by the wet granulation method in three formulas, there are F1 (extract dose 50 mg), F2 (extract dose 100 mg), and F3 (extract dose 150 mg), and compared with simvastatin tablets. The rats used in this study were 40 animals which were divided into 8 groups. Negative control group (induced of pork oil), F1 group, F2 group, F3 group, F4 group (placebo), positive control group (simvastatin 10 mg), base suspending agent group, and normal group.The average weight (mg) of F1 tablets (605.96 ± 9.94%), F2 (611.81 ± 12.33%), and F3 (639.09 ± 4.65%). As for the uniformity of size, all formulas have a diameter of 0.9 ± 0.0 (cm). for the hardness values of F1 (6.54 kg), F2 (5.31 kg), and F3 (5.43 kg). The value of friability F1 (0.8%), F2 (1.38%), and F3 (0.77%). While the disintegration time of F1 (13.31 minutes), F2 (19.48 minutes), and F3 (21.11 minutes). Whereas the dissolution rate (DE45) of each formulation decreased with increasing dose of extract, F1 (69.43%), F2 (64.95%), and F3 (60.04%). Extract contain quercetin as flavonoid, saponin, polyphenol, alkaloid, and tannin. Based on the results of statistical analysis, extract tablets did not differ significantly from simvastatin tablets in reducing total cholesterol levels. Tablet formulation of fig leaves extract with a dose variant has been shown to reduce total cholesterol in the blood between 18.3% until 37.98%.

Antidiabetic and hypolipidemic potential of Campomanesia xanthocarpa seed extract obtained by supercritical CO2.

Campomanesia xanthocarpa, a plant belonging to the Myrtaceae family, is popularly known as gabiroba. Leaves of gabiroba has been popularly used to treat various diseases, including inflammatory, renal, and digestive, among others. Additionally, studies have shown an effect to reduce blood cholesterol levels. The aim of this study was to evaluate the antihyperglycemic and hypolipidemic effects of Campomanesia xanthocarpa seed extract in hyperglycemic rats. The results showed that 400 mg/kg of seed extract was able to decrease blood glucose levels and to increase the muscular and hepatic glycogen content as well as to inhibit the sucrase and maltase activity. At doses of 200 mg/kg and 800 mg/kg, the activity of these enzymes was also reduced. In the lipid profile 400 mg/kg produced a decrease in total and LDL cholesterol serum levels; and with 200 mg/kg there was an increase in HDL cholesterol levels. The extract did not present hepatic and renal toxic effects at the different doses tested. The results suggest that the treatment with Campomanesia xanthocarpa seeds extract is useful in reducing glycemia, total cholesterol and LDL levels with potential adjuvant therapeutic in the treatment of diabetes and hypercholesterolemia, however, additional pharmacological and toxicological studies are still required.

Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model.

It is not yet clear whether plaque inflammation and cardiovascular events are reduced further when pioglitazone and atorvastatin are combined. Our study aimed to determine whether pioglitazone combined with atorvastatin can restrain the progression of atherosclerosis and promote plaque stabilization in a rabbit model. Thirty rabbits were randomly divided into an atherosclerosis group, an atorvastatin group, and an atorvastatin plus pioglitazone group. The atherosclerosis model was induced using balloon injury and feeding a high-fat diet. Plasma samples were then used to analyze glucose, triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), high-sensitivity C-reactive protein (hs-CRP), and matrix metalloproteinase-9 (MMP-9). The area percentage of atherosclerotic plaques was analyzed by hematoxylin-eosin staining. The relative reductions in TG and LDL-C and the increase in HDL-C levels were significantly greater in the combination therapy group than in the atorvastatin monotherapy group (TG: -33.60 ± 7.17% vs -24.16 ± 8.04%, p < 0.001; LDL-C: -42.89 ± 1.63% vs -37.13 ± 1.35%, p < 0.001; and HDL-C: 25.18 ± 5.53% vs 10.43 ± 6.31%, p < 0.001). The relative reductions in hs-CRP and MMP-9 levels were significantly greater in the combination therapy group than in the atorvastatin monotherapy group (-69.38 ± 1.06% vs-53.73 ± 1.92%, p < 0.001; -32.77 ± 2.49% vs -13.36 ± 1.66%, p < 0.001). The area percentage of atherosclerotic plaques was significantly smaller in the atorvastatin group (47.75%, p < 0.05) and in the atorvastatin plus pioglitazone group (22.57%, p < 0.05) than in the atherosclerosis group (84.08%, p < 0.05). We can thus conclude that the combination treatment of atorvastatin and pioglitazone provided additive benefits on inflammatory parameters and lipid metabolism. Pioglitazone combined with atorvastatin can further restrain the progression of atherosclerosis and promote plaque stabilization in a rabbit model.